Hyundai Pharmaceutical현대약품
004310 · KOSPI · ₩004310 · 현대약품
₩6,850▲ ₩150 (2.24%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 40.3% | 41.5% | 41.7% | 42.4% | 42.3% | 40.3% |
| Operating margin | 3.5% | 2.2% | 0.1% | 3.8% | 4.9% | −1.1% |
| Net margin | 1.4% | 1.3% | −0.3% | 3.4% | −0.1% | −2.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +5.5% | +9.1% | −2.8% | +11.1% | +16.4% | — |
| Operating income growth | +68.1% | +2,200.3% | −97.4% | −13.1% | +607.0% | — |
| Net income growth | +10.2% | +537.7% | −109.4% | +3,819.6% | +94.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 2.6% | 3.1% | −0.7% | 7.2% | −0.2% | −3.7% |
| Return on assets | 1.4% | 1.6% | −0.4% | 3.6% | −0.1% | −1.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 75.5% | 98.8% | 97.8% | 82.6% | 109.3% | 89.2% |
| Net debt to equity | 32.7% | 57.3% | 47.2% | 25.7% | 10.1% | 8.5% |
| Current ratio | 169.2% | 113.2% | 135.6% | 130.8% | 126.0% | 185.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Hyundai Pharmaceutical / 현대약품 / 004310 / KRX:004310
Source: KRX statistical information